Articles tagged with Neurotoxins
Researchers in China have discovered a new protein-based neurotoxin, anntoxin, found in the skin of the Chinese tree frog. This finding sheds light on the evolution of amphibians and poison, revealing a unique toxin that differs from other vertebrate animals.
Researchers have determined the atomic-level structure of botulinum neurotoxin subtype E, revealing a unique arrangement that may help explain its faster-acting properties. This finding could lead to the development of faster-acting vaccines and therapeutic agents.
A new ultrasensitive assay developed by City of Hope and California Department of Public Health can detect botulinum neurotoxin with high accuracy, improving food safety and diagnosis. The test is ten thousand times more sensitive than current methods and has potential applications in diagnosing other diseases.
Researchers have found a highly efficient inhibitor of botulinum neurotoxin type A, which can block its deadly action. The toxin binds to nerve cell membranes and cleaves proteins, causing muscle paralysis and death.
Researchers identified two small molecules with remarkable efficacy against botulinum neurotoxin A in animal models. The compounds showed surprisingly little activity in cell-based assays, highlighting the importance of animal-based studies. No significant side effects were observed with either molecule.
Scientists from Stanford University have discovered how botulinum neurotoxin binds to individual nerve cells, which could lead to the development of preventive vaccines against botulism. The study may also pave the way for novel remedies for several neuromuscular conditions, including cerebral palsy.
Two research teams discovered detailed views of the toxin plugged into its neuronal receptor, providing new information on how it shuts down neurons. The findings could aid efforts to engineer specialized versions of the neurotoxin used to treat various medical conditions.
Botulinum toxins bind to neurons, disrupting communication and leading to paralysis. The new study provides a structural glimpse of how these toxins recognize receptors on human neurons, offering a promising target for designing drugs to block their action.
Researchers have discovered a novel way to increase the potency of botulinum neurotoxin treatments, allowing for lower doses and enhanced cosmetic benefits. The new approach may reduce the risk of complications associated with frequent injections, making Botox safer and more accessible.
A research team led by Edwin R. Chapman identified the cellular receptor for botulinum neurotoxin A as SV2, a protein on actively recycling synaptic vesicles. This finding offers new insights into how the toxin shuts down nerve cells with deadly efficiency.
A team of researchers has identified how botulinum toxin, commonly known as botox, enters and affects neurons. The study reveals that the toxin binds to a protein called SV2, allowing it to gain entry into nerve cells.
Researchers at Scripps Research Institute have discovered small molecule activators of botulinum neurotoxin (BoNT), which could minimize dosage and reduce resistance. The findings hold promise for increasing the clinical efficacy of BoNT, a toxin with a range of therapeutic uses.
Researchers at Stanford University have solved part of the puzzle on how Botox works by binding to specific sites on proteins called SNAREs, preventing muscle contraction and paralysis. The study could help develop alternative treatments for botulism and find new medical applications for Botox and other neurotoxins.
Scientists have identified a key mechanism by which botulinum neurotoxin recognizes and attacks specific nerve cell proteins. The discovery reveals an extensive interaction between the toxin and its target, known as exosites, enabling high specificity.
Researchers at Brookhaven National Laboratory have deciphered the structure of botulinum toxin, shedding light on its mechanism of action. By modifying a single amino acid, scientists created an inactive form of the toxin that retains structural similarity to the active form, paving the way for potential vaccine development.
Researchers found that 68% of patients experienced a reduction in pain intensity of greater than 33%, indicating promising relief. The biotoxin blocks slow sodium channel nocicipetive pain fibers in a highly selective way, making it a potential treatment option for cancer pain.
Researchers have developed a device, known as a micromechanosensor, that allows for rapid detection of botulism toxins, which can cut detection time from days to minutes. This could lead to more effective treatment and lower mortality rates among those afflicted.
Researchers have identified compounds that inhibit the enzymatic action of botulinum neurotoxin serotype A light chain (BoNT/A LC), a crucial step towards developing new therapeutics. The findings hold promise for treating botulism and other muscle dysfunctions in humans.
Researchers found BMAA in increasingly higher concentrations in the food chain of Chamorro people on Guam, potentially linking their diet to neurodegenerative diseases like ALS-PDC. Biomagnification of BMAA was also detected in Canadian patients with similar conditions.
Researchers at University of Wisconsin-Madison identify a receptor for botulinum neurotoxin B, allowing for improved medical uses and prevention against biological threats. The discovery enables the development of antidotes and protective agents to neutralize the toxin.
Researchers found high concentrations of BMAA in bat skins, which may have contributed to the Chamorro people's increased risk of ALS/PDC. The findings support a hypothesis linking flying foxes to the disease.